The Sustainable Nutrition Group Ltd (TSN)
Alchemia Limited (ASX: ACL) is a drug discovery and development company. Its lead drug fondaparinux is a generic version of GlaxoSmithKline’s Arixtra®, a synthetic anticoagulant mainly used for preventing deep vein thrombosis.
Fondaparinux was approved by the FDA and launched in July 2011 in the USA by Alchemia’s marketing partner Dr Reddy’s Laboratories. Alchemia’s asset pipeline is built on two platform technologies: HyACT® (targeted cancer delivery) and VAST® (drug discovery). The lead product from the HyACT platform is HA-Irinotecan for which a Phase III clinical trial in metastatic colorectal cancer is currently in progress.
Additional Research
Nomura Equity Research Report 2 Apr 2012
Southern Cross Equities Report 11 Jul 2011